Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations

PURPOSE: Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib and its active metabolite (M5) in pediatric patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneses-Lorente, Georgina, Guerini, Elena, Mercier, Francois, Parrott, Neil, Kowalski, Karey, Chow-Maneval, Edna, Buchheit, Vincent, Bergthold, Guillaume, Fox, Elizabeth, Phipps, Alex, Djebli, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033473/
https://www.ncbi.nlm.nih.gov/pubmed/36884068
http://dx.doi.org/10.1007/s00280-023-04510-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033473/
https://www.ncbi.nlm.nih.gov/pubmed/36884068
http://dx.doi.org/10.1007/s00280-023-04510-1

Ejemplares similares